Evaluation of the Effect of Lorlatinib on CYP2B6, CYP2C9, UGT, and P-Glycoprotein Substrates in Patients with Advanced Non-Small Cell Lung Cancer

CONCLUSIONS: Lorlatinib is a net moderate inducer of P-gp and a weak inducer of CYP2B6, CYP2C9, and UGT after steady state is achieved with daily dosing. Medications that are P-gp substrates with a narrow therapeutic window should be avoided in patients taking lorlatinib; no dose modifications are needed with substrates of CYP2B6, CYP2C9, or UGT.CLINICALTRIALS: gov: NCT01970865.PMID:38079095 | DOI:10.1007/s40262-023-01309-4

Source: Clinical Lung Cancer - December 11, 2023 Category: Cancer & Oncology Authors: Joseph Chen Alessandra Bearz Dong-Wan Kim Hirva Mamdani Jessica Bauman Rita Chiari Sai-Hong Ignatius Ou Benjamin J Solomon Ross A Soo Enriqueta Felip Alice T Shaw Holger Thurm Jill S Clancy Kimberly Lee Melissa O'Gorman Cherie Tanski Yazdi K Pithavala Source Type: research